AN2 Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst on August 13. Analyst Joseph Schwartz from Leerink Partners maintained a Hold rating on the stock and has a $1.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Schwartz has given his Hold rating due to a combination of factors related to AN2 Therapeutics, Inc.’s current progress and financial position. The company is making strides in its early-stage infectious disease and oncology programs, with significant developments in treatments for Chagas disease and melioidosis. However, these advancements are still in the early phases, with the full Phase 1 trial for Chagas disease expected to conclude by the end of 2025.
Additionally, AN2 is in discussions for government funding for a Phase 2 trial for melioidosis, which indicates potential but also uncertainty regarding future financial support. Financially, AN2 reported a net loss for the quarter, which may contribute to a cautious outlook. While there is potential for growth, the current stage of their projects and financial results suggest a Hold rating is prudent until further progress is made.
ANTX’s price has also changed slightly for the past six months – from $1.070 to $1.050, which is a -1.87% drop .